港股异动丨微创医疗涨逾6% 旗下科创板公司心脉医疗首三季多赚48%
格隆汇10月28日丨微创医疗(0853.HK)涨逾6%,报8.1港元,成交3343万港元,总市值131亿港元。

首批登陆科创板的上市公司心脉医疗昨日发布2019年三季度报告,今年前三季度,公司实现营业收入2.48亿元,同比增长43%;归属于上市公司股东的净利润1.13亿元,同比增长48%;归属于上市公司股东的扣除非经常性损益的净利润1.02亿元,同比增长43%;基本每股收益1.94元。公开资料显示,心脉医疗系微创医疗的下属子公司,主要从事主动脉及外周血管介入医疗器械的研发、生产和销售,主营产品为大动脉覆膜支架系统、术中支架系统、大球囊及周围血管支架等产品。微创医疗创始人、董事局主席常兆华曾表示,心脉医疗就是微创医疗所生产出的“公司产品”,是第一个比较成熟的、能够走向市场的产品。未来可能还会有很多类似的产品,等壮大了就逐一放出去。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.